In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
News|Podcasts|April 2, 2026
ACT Brief: Platform vs. Bespoke Technology, Patient and Site Experience Design, and AI-Driven ADC Development
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we explore how to decide which trial complexities warrant core technology platforms versus custom configurations, how measuring patient and site experiences early identifies actionable solutions, and Daiichi Sankyo's collaboration with Tempus to improve ADC patient selection through AI.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In the final segment of her video
interview , Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, offered a framework for deciding which emerging trial complexities should be built into core technology platforms and which are better managed as bespoke configurations. - In part two of her
series , Olga Elizarova, DDS, MPH, MBA, senior consultant behavioral science at S3 Connected Health, examined how poor patient and site experiences with confusing information, unreliable technology, and inefficient processes drive disengagement and dropout. Using mixed-method research combining quantitative and qualitative feedback, sponsors can identify sources of friction early and apply behavioral science to develop evidence-based solutions that improve trial performance. - Daiichi Sankyo and Tempus AI announced a
collaboration to apply multimodal AI and real-world data to ADC development, focusing on biomarker discovery and patient stratification. The partnership aims to generate response maps across diverse patient populations, enabling more precise cohort identification and more efficient clinical trial design in increasingly competitive oncology pipelines.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Trending on Applied Clinical Trials Online
1
Syneos Health, Optum Partner on Adaptive Clinical Development Model
2
Where AI Governance in Clinical Development Falls Short
3
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
4
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
5